Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Testa

Showing results (561-570 of 588) with videos related to

Pageof 59
Sort By:
Cancer Research|December 28, 2013
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axisCraig W Menges, Yuwaraj Kadariya, Deborah Altomare, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2012
CD45-deficient severe combined immunodeficiency caused by uniparental disomyJoseph L Roberts, Rebecca H Buckley, Biao Luo, et al.
Genes, Chromosomes & Cancer|July 9, 2009
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumorsMartin G Belinsky, Yuliya V Skorobogatko, Lori Rink, et al.
Science Translational Medicine|May 23, 2014
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationshipIrina M Shapiro, Vihren N Kolev, Christian M Vidal, et al.
Molecular and Cellular Biology|January 11, 2007
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 proteinHansoo Lee, Donghwa Kim, Han C Dan, et al.
The FEBS Journal|March 7, 2013
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinomaLei Ma, Gong Zhang, Xiao-Bo Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer modelsSeiji Mabuchi, Masahide Ohmichi, Yukihiro Nishio, et al.
International Journal of Cancer|August 22, 1995
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomasA Bellacosa, D de Feo, A K Godwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Somatic Epigenetic Silencing of <i>RIPK3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant MesotheliomaYinfei Tan, Eleonora Sementino, Mitchell Cheung, et al.
Genes, Chromosomes & Cancer|May 13, 2011
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Lin Zhang, Joel Greshock, et al.
Pageof 59

Showing results (561-570 of 588) with videos related to

Sort By:
Pageof 59
Cancer Research|December 28, 2013
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axisCraig W Menges, Yuwaraj Kadariya, Deborah Altomare, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2012
CD45-deficient severe combined immunodeficiency caused by uniparental disomyJoseph L Roberts, Rebecca H Buckley, Biao Luo, et al.
Genes, Chromosomes & Cancer|July 9, 2009
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumorsMartin G Belinsky, Yuliya V Skorobogatko, Lori Rink, et al.
Science Translational Medicine|May 23, 2014
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationshipIrina M Shapiro, Vihren N Kolev, Christian M Vidal, et al.
Molecular and Cellular Biology|January 11, 2007
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 proteinHansoo Lee, Donghwa Kim, Han C Dan, et al.
The FEBS Journal|March 7, 2013
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinomaLei Ma, Gong Zhang, Xiao-Bo Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer modelsSeiji Mabuchi, Masahide Ohmichi, Yukihiro Nishio, et al.
International Journal of Cancer|August 22, 1995
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomasA Bellacosa, D de Feo, A K Godwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Somatic Epigenetic Silencing of <i>RIPK3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant MesotheliomaYinfei Tan, Eleonora Sementino, Mitchell Cheung, et al.
Genes, Chromosomes & Cancer|May 13, 2011
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Lin Zhang, Joel Greshock, et al.
Pageof 59